HomeComparePBIGF vs ORCC

PBIGF vs ORCC: Dividend Comparison 2026

PBIGF yields 1111.11% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PBIGF wins by $47499206.05M in total portfolio value
10 years
PBIGF
PBIGF
● Live price
1111.11%
Share price
$0.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47499206.07M
Annual income
$40,354,669,257,990.61
Full PBIGF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — PBIGF vs ORCC

📍 PBIGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBIGFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBIGF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PBIGF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBIGF
Annual income on $10K today (after 15% tax)
$94,444.44/yr
After 10yr DRIP, annual income (after tax)
$34,301,468,869,292.02/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, PBIGF beats the other by $34,301,468,869,291.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBIGF + ORCC for your $10,000?

PBIGF: 50%ORCC: 50%
100% ORCC50/50100% PBIGF
Portfolio after 10yr
$23749603.05M
Annual income
$20,177,334,628,995.83/yr
Blended yield
84.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

PBIGF
No analyst data
Altman Z
-20.2
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBIGF buys
0
ORCC buys
0
No recent congressional trades found for PBIGF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBIGFORCC
Forward yield1111.11%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$47499206.07M$21.4K
Annual income after 10y$40,354,669,257,990.61$1.04
Total dividends collected$46960998.57M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: PBIGF vs ORCC ($10,000, DRIP)

YearPBIGF PortfolioPBIGF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$121,811$111,111.11$11,190$489.61+$110.6KPBIGF
2$1,395,251$1,264,912.89$12,229$256.01+$1.38MPBIGF
3$15,033,652$13,540,734.05$13,216$130.74+$15.02MPBIGF
4$152,440,880$136,354,872.42$14,207$66.02+$152.43MPBIGF
5$1,455,294,162$1,292,182,420.27$15,234$33.17+$1455.28MPBIGF
6$13,086,105,030$11,528,940,276.13$16,317$16.62+$13086.09MPBIGF
7$110,889,069,345$96,886,936,963.27$17,468$8.32+$110889.05MPBIGF
8$885,941,741,006$767,290,436,806.24$18,695$4.16+$885941.72MPBIGF
9$6,677,137,211,537$5,729,179,548,660.89$20,006$2.08+$6677137.19MPBIGF
10$47,499,206,074,335$40,354,669,257,990.61$21,407$1.04+$47499206.05MPBIGF

PBIGF vs ORCC: Complete Analysis 2026

PBIGFStock

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Full PBIGF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this PBIGF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBIGF vs SCHDPBIGF vs JEPIPBIGF vs OPBIGF vs KOPBIGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.